Ipilimumab is a human monoclonal IgG1 antibody against CTLA-4 that has been shown to prolong the overall survival of advanced melanoma. The most common adverse events associated with ipilimumab are immune-related. Severe hematological toxicity is rare. We report a case of severe neutropenia following ipilimumab therapy that fully resolved after the administration of prednisone, cyclosporine, and anti-thymocyte globulin therapies.
CITATION STYLE
Ban-Hoefen, M., Burack, R., Sievert, L., & Sahasrabudhe, D. (2016). Ipilimumab-induced neutropenia in melanoma. Journal of Investigative Medicine High Impact Case Reports, 4(3). https://doi.org/10.1177/2324709616661835
Mendeley helps you to discover research relevant for your work.